Clin2
NCT07753993Possibly a fitNot yet recruiting

Study of elecoglipron for chronic kidney disease

Chronic Kidney Disease

Treatments studied

Part of Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests an investigational medicine called elecoglipron for people with chronic kidney disease. It aims to see if it can improve kidney health compared to a placebo (inactive pill) and may be an option for those already on standard blood pressure and kidney protective medications.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
7,000 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Adults with chronic kidney disease, including a urine protein level of 30 mg/g or higher and an estimated kidney function (eGFR) of 20 or more (units will be checked)
  • Must be on a stable, maximally tolerated dose of an ACE inhibitor or ARB (kidney protective blood pressure medicines) for at least 4 weeks before screening
  • Body mass index (BMI) of 23 or higher
  • No history of type 1 diabetes
  • Recent blood sugar (HbA1c) less than 10%
  • No active treatment for diabetic eye disease (retinopathy or macular edema)
  • No more than one severe low blood sugar event in the last 6 months and no unawareness of low blood sugar
  • No heart attack, stroke, or major heart procedure in the last 3 months
  • No significant stomach or intestinal condition, and not taking medicines that affect stomach emptying
  • No history of pancreatitis or certain types of thyroid cancer (medullary thyroid cancer or MEN2)
  • Not currently participating in another clinical trial

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07107945Recruiting· Phase 3
Study of empagliflozin for children with chronic kidney disease

This trial tests if empagliflozin, a daily pill, is safe and helps children ages 2–17 with chronic kidney disease (CKD). Your child may be eligible if they have reduced kidney function and elevated protein in their urine, and are already on stable kidney treatments.

Birmingham, Alabama
NCT07625774Not yet recruiting· Phase 3
Testing a new oral GLP-1 medication for kidney disease

This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.

Tianjin, Tianjin Municipality
NCT07694544Recruiting· Phase 1
Oral EC5026 study in people with kidney disease

This trial tests a medication called EC5026 in people with and without chronic kidney disease (CKD) to see how the body handles it. It helps understand if dose adjustments are needed for people with impaired kidney function.

Sacramento, California
NCT07419828Recruiting· Phase 3
Study of HRS-1780 for chronic kidney disease

This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.

Nanjing, Jiangsu
NCT07241390Recruiting· Phase 3
Study of orforglipron for heart and kidney health.

This trial tests if orforglipron can reduce the risk of heart attack, stroke, or kidney failure in people with heart disease or chronic kidney disease.

Bahía Blanca
NCT07662044Recruiting· Phase 3
Studying elecoglipron for type 2 diabetes

This trial tests a new medicine called elecoglipron, taken alone or with another diabetes drug (dapagliflozin), to see if it helps control blood sugar better than a placebo. It may be an option if your current treatment isn't working well enough.

Birmingham, Alabama

Hear when a new Chronic kidney disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.